Chronic treatment with PDGF-BB and endothelin-1 synergistically induces vascular hyperplasia and loss of contractility in organ-cultured rat tail artery

Atherosclerosis

Volumn 214, Issue 2, 2011, Pages 288-294

  Kida, Taiki ^a   Chuma, Hiroko ^a   Murata, Takahisa ^a   Yamawaki, Hideyuki ^a   Matsumoto, Shigeko ^a   Hori, Masatoshi ^a   Ozaki, Hiroshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Akt; Endothelin 1; ERK1 2; MTOR; Organ culture; PDGF BB; Vascular smooth muscle

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ALPHA ACTIN; BETA ACTIN; ENDOTHELIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NORADRENALIN; PLATELET DERIVED GROWTH FACTOR BB; POTASSIUM ION; PROTEIN KINASE B; PROTEIN P70; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTERY CONSTRICTION; ARTERY MEDIA; ARTERY RUPTURE; ARTICLE; CELL PROLIFERATION; CHRONIC DISEASE; DOSE RESPONSE; ENZYME PHOSPHORYLATION; EXPERIMENT; HYPERPLASIA; LONG TERM CARE; MALE; MAMMAL; MUSCLE CELL; NONHUMAN; ORGAN CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; THROMBOCYTE; TISSUE LEVEL; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; ARTERIES; BLOTTING, WESTERN; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENDOTHELIN-1; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; ORGAN CULTURE TECHNIQUES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TAIL; TIME FACTORS; TOR SERINE-THREONINE KINASES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 79151478066     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.11.001     Document Type: Article

References (30)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
2. Muto A., Fitzgerald T.N., Pimiento J.M., et al. Smooth muscle cell signal transduction: implications of vascular biology for vascular surgeons. J Vasc Surg 2007, 45(Suppl. A):A15-A24.
3. Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004, 84:767-801.
4. Heldin C.H., Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999, 79:1283-1316.
5. Jawien A., Bowen-Pope D.F., Lindner V., Schwartz S.M., Clowes A.W. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992, 89:507-511.
6. Kaplan-Albuquerque N., Garat C., Desseva C., Jones P.L., Nemenoff R.A. Platelet-derived growth factor-BB-mediated activation of Akt suppresses smooth muscle-specific gene expression through inhibition of mitogen-activated protein kinase and redistribution of serum response factor. J Biol Chem 2003, 278:39830-39838.
7. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
8. Hirata Y., Takagi Y., Fukuda Y., Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989, 78:225-228.
9. Ohlstein E.H., Arleth A., Bryan H., Elliott J.D., Sung C.P. The selective endothelin ETA receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogenesis. Eur J Pharmacol 1992, 225:347-350.
10. McKenna C.J., Burke S.E., Opgenorth T.J., et al. Selective ET(A) receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model. Circulation 1998, 97:2551-2556.
11. Yahiaoui L., Villeneuve A., Valderrama-Carvajal H., Burke F., Fixman E.D. Endothelin-1 regulates proliferative responses, both alone and synergistically with PDGF, in rat tracheal smooth muscle cells. Cell Physiol Biochem 2006, 17:37-46.
12. Liu Y, Li M., Warburton R.R., Hill N.S., Fanburg B.L. The 5-HT transporter transactivates the PDGFbeta receptor in pulmonary artery smooth muscle cells. FASEB J 2007, 21:2725-2734.
13. Li X., Tsai P., Wieder E.D., et al. Vascular smooth muscle cells grown on Matrigel. A model of the contractile phenotype with decreased activation of mitogen-activated protein kinase. J Biol Chem 1994, 269:19653-19658.
14. Sakamoto K., Murata T., Chuma H., Hori M., Ozaki H. Fluvastatin prevents vascular hyperplasia by inhibiting phenotype modulation and proliferation through extracellular signal-regulated kinase 1 and 2 and p38 mitogen-activated protein kinase inactivation in organ-cultured artery. Arterioscler Thromb Vasc Biol 2005, 25:327-333.
15. Owens G.K. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 1995, 75:487-517.
16. Chen C.N., Li Y.S., Yeh Y.T., et al. Synergistic roles of platelet-derived growth factor-BB and interleukin-1beta in phenotypic modulation of human aortic smooth muscle cells. Proc Natl Acad Sci USA 2006, 103:2665-2670.
17. Blaschke F., Stawowy P., Kappert K., et al. Angiotensin II-augmented migration of VSMCs towards PDGF-BB involves Pyk2 and ERK 1/2 activation. Basic Res Cardiol 2002, 97:334-342.
18. Jahan H., Kobayashi S., Nishimura J., Kanaide H. Endothelin-1 and angiotensin II act as progression but not competence growth factors in vascular smooth muscle cells. Eur J Pharmacol 1996, 295:261-269.
19. Komuro I., Kurihara H., Sugiyama T., Yoshizumi M., Takaku F., Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988, 238:249-252.
20. Yang Z., Krasnici N., Luscher T.F. Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation 1999, 100:5-8.
21. Zhan Y., Kim S., Izumi Y., et al. Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration, and gene expression. Arterioscler Thromb Vasc Biol 2003, 23:795-801.
22. Nabel E.G, Yang Z., Liptay S., et al. Recombinant platelet-derived growth factor B gene expression in porcine arteries induce intimal hyperplasia in vivo. J Clin Invest 1993, 91:1822-1829.
23. Reidy M.A., Fingerle J., Lindner V. Factors controlling the development of arterial lesions after injury. Circulation 1992, 86:III43-III46.
24. Calabro P., Samudio I., Willerson J.T., Yeh E.T. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004, 110:3335-3340.
25. Campbell M., Trimble E.R. Modification of PI3K- and MAPK-dependent chemotaxis in aortic vascular smooth muscle cells by protein kinase CbetaII. Circ Res 2005, 96:197-206.
26. Martin K.A., Rzucidlo E.M., Merenick B.L., et al. The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Am J Physiol Cell Physiol 2004, 286:C507-C517.
27. Shan J., Nguyen T.B., Totary-Jain H., Dansky H., Marx S.O., Marks A.R. Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors. Proc Natl Acad Sci USA 2008, 105:19006-19011.
28. Memmott R.M., Dennis P.A. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal 2009, 21:656-664.
29. Loirand G., Guerin P., Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006, 98:322-334.
30. Seasholtz T.M., Majumdar M., Kaplan D.D., Brown J.H. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 1999, 84:1186-1193.